In vitro 1H and 31P NMR spectroscopic evidence of multiple aberrant biochemical pathways in murine trisomy 16 brain development.
Nuclear magnetic resonance (NMR) spectroscopy was used to evaluate cytosolic compounds and membrane phospholipids simultaneously in trisomy 16 (Ts16) and euploid (control) murine brain at fetal day 15 in order to examine the cellular biochemistry that underlies the neurodevelopmental consequences of chromosome triplication in this model of Down syndrome (DS). Proton NMR spectroscopic analysis of brain tissue extracts demonstrated decreased levels of choline and increased levels of myo-inositol (MI) in Ts16 brains compared with control. These data are consistent with the cholinergic deficits and elevated MI levels previously described in Ts16. Compared with euploid brains. Ts16 brains also possess higher levels of creatine, adenosine, and tyrosine. Increased levels of MI and creatine, compounds that are localized to glia, imply abnormalities in the trophic environment of Ts16 brain. Phosphorus NMR spectroscopic analysis of extracts further revealed elevated levels of anionic phospholipid membrane components, such as phosphatidylinositol (PtdIno) and phosphatidylethanolamine, in Ts16 brains. Since these compounds are confined to the inner leaflet of the membrane, the findings suggest that membrane composition is altered specifically in the cytosolic bilayer at this stage. Together our proton and phosphorus NMR spectroscopic results indicate that multiple biochemical pathways are affected in Ts16 brain development. Understanding the effects of these aberrations may elucidate the processes that lead to neural dysfunction and Alzheimer's disease (AD) neuropathology in DS individuals.
Yao
F S
FS
Department of Psychiatry and Behavioral Sciences, Northwestern University Medical School, Chicago, IL 60611, USA. faith@cmr.nunet.net
Caserta
M T
MT
Wyrwicz
A M
AM
D000409:Alanine / Q000032:analysis; D000818:Animals; D001224:Aspartic Acid / Q000032:analysis; D015415:Biomarkers; D001923:Brain Chemistry / Q000235:genetics*; D002794:Choline / Q000032:analysis; D003401:Creatine / Q000032:analysis; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000378:metabolism; D005260:Female; D018698:Glutamic Acid / Q000032:analysis; D066298:In Vitro Techniques; D015544:Inositol 1,4,5-Trisphosphate / Q000032:analysis; D019344:Lactic Acid / Q000032:analysis; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D010759:Phosphorus Isotopes; D011522:Protons; D013654:Taurine / Q000032:analysis; D013912:Threonine / Q000032:analysis; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D015415:Biomarkers; D010759:Phosphorus Isotopes; D011522:Protons; D013654:Taurine; D013912:Threonine; D001224:Aspartic Acid; D019344:Lactic Acid; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D015544:Inositol 1,4,5-Trisphosphate; D003401:Creatine; D002794:Choline; D000409:Alanine